Source comparison
BPC-157 Muscle Recovery Protocol Dosage Timing: Comparison of Methods
Subcutaneous (local) 250–500mcg per injection High. Administered within 30–60 min post-injury or post-training 15–30 minutes for local tissue effects Acute injuries (strains, tears, tendon damage) requiring site-specific healing Requires proper injection techn
This comparison does not assign a generated winner or score.
- Subcutaneous (local)
- 250–500mcg per injection
- High. Administered within 30–60 min post-injury or post-training
- 15–30 minutes for local tissue effects
- Acute injuries (strains, tears, tendon damage) requiring site-specific healing
- Requires proper injection technique; minor discomfort at injection site
- Subcutaneous (distal)
- Moderate. Can be administered on a fixed schedule
- 30–60 minutes for systemic distribution
- Chronic overuse injuries, diffuse soft tissue inflammation
- Lower tissue concentration at injury site compared to local injection
- Intramuscular
- 300–600mcg per injection
- Moderate. Slower absorption reduces timing sensitivity
- 45–90 minutes
- Larger muscle injuries or when subcutaneous access is limited
- Slower onset; less predictable for acute-phase intervention
- Oral (capsule/tablet)
- 500–1000mcg per dose
- Low. Gastric absorption is inconsistent
- Unknown in humans (60–120 min estimated)
- Convenience for non-acute maintenance protocols
- Bioavailability unverified in humans; unreliable for time-sensitive protocols
- The comparison shows that subcutaneous administration near the injury site offers the tightest control over BPC-157 muscle recovery protocol dosage timing, which is why research-grade protocols default to this method.